Condition
Postural Tachycardia Syndrome (POTS)
Total Trials
6
Recruiting
3
Active
3
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (2)
P 1 (1)
P 2 (3)
Trial Status
Recruiting3
Terminated1
Unknown1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07189936Phase 2Recruiting
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
NCT05421208Not ApplicableRecruiting
Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome
NCT05375968Phase 2RecruitingPrimary
Splanchnic Venous Capacitance in Postural Tachycardia Syndrome
NCT02558972Phase 2TerminatedPrimary
Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)
NCT01550315Not ApplicableCompletedPrimary
Effect of Dietary Sodium Intake on Vascular Endothelium
NCT02854683Phase 1Unknown
Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients
Showing all 6 trials